Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 428, 267-269 (18 March 2004) | doi:10.1038/428267a
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Assistant or Associate Professor of Neurobiology
- Medical College of Georgia
- Augusta, GA United States
Academic Surgical Pathologists GI / Breast / GYN
- Medical College of Wisconsin
- Milwaukee, Wisconsin, USA
Cancer: Survival pathways meet their end
Frank McCormick1
Top of page
Abstract
Conventional chemotherapeutic approaches to treating tumours can be hit-and-miss. One way to ensure successful treatment may be to go for the jugular of cancer-cell survival signalling as well.
Chemotherapy uses powerful drugs designed to induce cancer cells to commit suicide. So why don't all tumours succumb to these drugs?
- Frank McCormick is at the Comprehensive Cancer Center, University of California, San Francisco, Box 0128, 2340 Sutter Street, San Francisco, California 94143, USA.
e-mail: Email: mccormick@cc.ucsf.edu
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathwaysNature Medicine Article (01 Jun 2004)
Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53The EMBO Journal Article (28 Nov 2007)
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapyNature Letters to Editor (18 Mar 2004)
See all 12 matches for Research